Previous 10 | Next 10 |
2023-06-27 15:09:00 ET Regeneron ( NASDAQ: REGN ) announced Tuesday that the U.S. Food and Drug Administration (FDA) declined to approve an 8 mg dose of its eye disease therapy, aflibercept. The injection at a dose of 2 mg is already marketed in the U.S. as Eylea for conditions ...
89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years Of those assigned to a 16-week dosing regimen at baseline, 83% maintained ≥16-week dosing intervals through two years Many patients met the extension criteria for even longe...
No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL No additional clinical data or trials have been requested TARRYTOWN, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
2023-06-14 14:39:07 ET Regeneron Pharmaceuticals Inc. (REGN) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ET Company Participants Ryan Crowe - VP, IR Bob Landry - EVP & CFO Marion McCourt - EVP & Head of Commercial C...
2023-06-14 10:00:00 ET The first half of the year is almost over -- and so far, 2023 has been pretty kind to investors. Broader equity markets bounced back from last year's nightmare while economic pressures, notably inflation, cooled off. Still, some may worry that there are issues ahead, ...
2023-06-13 17:55:37 ET Summary Regeneron Pharmaceuticals, Inc. has potential to receive FDA approval of higher dosing of 8 mg of EYLEA, which has been set with an FDA target action date of June 27, 2023. The additional indication in preterm infants with retinopathy of prematurity ...
2023-06-12 15:01:57 ET Ocular Therapeutix ( NASDAQ: OCUL ) lost ~9% on Monday after announcing 12-month data from its Phase 1 clinical trial for eye implant OTX-TKI in patients with wet age-related macular degeneration (wet AMD), a leading cause of blindness. Citing data as ...
2023-06-09 12:32:12 ET Summary Today, we take our first look at a commercial stage biopharma concern called Kiniksa Pharmaceuticals, Ltd. The company is seeing impressive growth from its primary drug asset and has an intriguing pipeline. An investment analysis follows in the p...
2023-06-09 09:26:24 ET The Biden administration on Friday published a list of Medicare Part B drugs that will be subject to inflation penalties for Q3 2023, including some of the products from AbbVie ( NYSE: ABBV ) and Amgen ( NASDAQ: AMGN ) in the list of 43 medications. ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...